Clinical Scorecard: Hypoxia-Driven Activation of DNMT3B and SHP2 Pathways Enhances Hepatocellular Carcinoma Progression by Inhibiting P53 and MYH11 Protein Levels
At a Glance
Category
Detail
Condition
Key Mechanisms
Activation of AKT/DNMT3B/SHP2 pathway modulating P53 expression.
Target Population
Care Setting
Key Highlights
High HIF1A expression correlates with DNMT3B upregulation and MYH11 silencing.
High axis score indicates shorter overall survival.
CBFβ-MYH11 regulates the AKT/DNMT3B/SHP2 pathway to modulate P53 expression.
MYH11 acts as a tumor suppressor with poor expression in hepatocellular carcinoma.
Guideline-Based Recommendations
Diagnosis
Utilize ultrasonography and alpha-fetoprotein (AFP) for early detection of HCC.
Management
Consider liver transplantation, interventional therapy, and catheter arterial embolization for treatment.
Monitoring & Follow-up
Regular monitoring of tumor markers and imaging for disease progression.
Risks
Risk factors include viral infections, chronic liver disease, alcohol abuse, and metabolic diseases.
Patient & Prescribing Data
Patients with advanced hepatocellular carcinoma.
Limited treatment options available for advanced stages.
Clinical Best Practices
Early identification of HCC is crucial for better prognosis.
